Clinical trial · Interventional
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Clinical Study of CD19/CD20 Bispecific Nanobody-derived CAR-T Cells in Refractroy/Relasped B Cell Lymphoma
NCT03881761CI-TRIAL-00037734unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-Cell Lymphoma Stage I | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Refractory | — | UNRESOLVED | — |
| Relapsed | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CD19/CD20 bispecific CAR-T cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- experimental arm
- description
- CAR-T cell group
- interventionNames
- Biological: CD19/CD20 bispecific CAR-T cells
Primary outcomes (1)
- measure
- occurrence of study related adverse events
- timeFrame
- one year
- description
- safety of CAR-T cells
Secondary outcomes (3)
- measure
- objective response rate
- timeFrame
- three months
- description
- proportion of patients with complete response and partial response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * expected lifetime\>3 months * CD19/CD20 positive relapsed/refractory B cell lymphoma * KPS\>70 * at least one measurable lesion according to RECIST 1.1 * enough function of hear, liver, kidney and bone marrow * no history of severe allergies * no other history of malignancy * no other diseases that conflict with this regimen * no serious mental illness * patient or family member sign informed consent Exclusion Criteria: * Pregnant or lactating women * Severe infectious or viral disease * Active B or C viral hepatitis * Patients who have used large amounts of glucocorticoids or other immunosuppressive agents during the last 4 weeks * participated in other clinical studies in the last 3 months, or have been treated with other gene products * Others not appropriate to participate in this study examined by the investigators
References
Publications (0)
Data not yet available
No reference posted for this study.